HOME >> MEDICINE >> NEWS
Researchers Begin Drug Trial In Hope Of Finding New Ways To Treat Acute Kidney,,Failure

DALLAS, Texas.--Each year 20 million Americans are affected by kidney and urological diseases, while 150,000 develop acute kidney failure. The current treatment for kidney failure is dialysis, a sometimes painful and always costly stop-gap measure that is not a cure, or kidney transplant.

Dr. Robert Star, a UT Southwestern Medical Center at Dallas researcher, has been awarded $40,000 per year for the next three years to study a drug that has reversed the onset of acute kidney failure in animals.

"With the mortality rate being anywhere from 25 percent to 50 percent for individuals who develop acute renal failure, new methods for detecting, preventing and treating acute renal failure must be sought," said Star, associate professor of internal medicine.

The National Kidney Foundation estimates there are 53,000 Americans waiting for life- saving transplants, and 10 people die each day while waiting. Star's research involving the drug alpha-MSH could reduce the disparity of organ allocation in this country that results in unnecessary deaths. "We have found that alpha-MSH treatment significantly reduced renal damage and inhibited the disease at a number of different steps even in transplanted kidneys," Star said.

"This means that a less-than-perfect kidney could be transplanted. It could help increase the number of available kidneys, which would reduce the waiting list for recipients considerably," Star said.

Phase I of the study, funded by the Baxter Extramural Grant Program, will evaluate the drug in four groups of people: dialysis patients, kidney-transplant patients, patients that already have acute renal failure and people without kidney damage.

Star also has developed a new way of testing kidney function. The conventional method can take up to three hours but is not practical for patients with acute kidney failure, which can strike within days or even hours.

"This new procedure meas
'"/>

Contact: Ione Echeverria
ione.echeverria@email.swmed.edu
(214) 648-3404
UT Southwestern Medical Center
18-Aug-1998


Page: 1 2

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. Researchers close in on breast cancer vaccine
4. Researchers discover link between insulin and Alzheimers
5. Researchers model brains electrical storm during a seizure
6. Researchers track programs success in curbing aggressive behavior
7. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
8. Researchers offer emergency workers a lifeline
9. Researchers discover genetic variant that may explain why women develop M.S. more than men
10. Researchers map the sexual network of an entire high school
11. Researchers hope monkeys can provide new insights into depression

Post Your Comments:
(Date:11/22/2014)... Dallas, TX (PRWEB) November 22, 2014 ... Society (ICS) as the complaint that the individual ... times for voiding. The report “Nocturia – Pipeline ... therapeutic development for Nocturia, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:11/22/2014)... York, New York (PRWEB) November 22, 2014 ... of power morcellators ( http://www.morcellatorlawsuit2015.com ) in minimally-invasive ... 450 new signatures since the end of October, Bernstein ... had signed the petition as of November 21st, 2014. ... 31st, when 86,042 supporters had signed on to the ...
(Date:11/22/2014)... wide variety and complexity of foods served at holiday ... allergies, an expert warns. "Every person is different ... that it can be really difficult to avoid all ... allergy and clinical immunology at Wake Forest Baptist Medical ... you know you have food allergies, caution should overrule ...
(Date:11/22/2014)... York, New York (PRWEB) November 22, 2014 ... filed on behalf of patients who allegedly developed Type ... forward in the federal multidistrict litigation now underway in ... LLP reports. According to court documents, the litigation will ... 10:00 a.m. The Court has directed Lead Counsel for ...
(Date:11/22/2014)... Hastings and Hastings, a discount accident attorney in ... with the option of leaving an online review using ... and easy to navigate website that has recently been ... allows clients to research the Hastings and Hastings law ... when retaining an attorney. Those who have been injured ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3
(Date:11/21/2014)... Nov. 21, 2014 Clementia ... Medicines Agency (EMA) has granted Orphan Medicinal ... product candidate, for the treatment of fibrodysplasia ... severely disabling genetic disease characterized by painful, ... and new abnormal bone formation. This process, ...
(Date:11/21/2014)... IRVINE, Calif. , Nov. 20, 2014  Edwards ... leader in the science of heart valves and hemodynamic ... corporate giving in 2014 to support a strong launch ... Heartbeat Matters , and to improve the global communities ... In 2014, Edwards, global corporate giving will exceed $8 ...
(Date:11/21/2014)... /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced today ... be presenting at the 26 th Annual Piper Jaffray ... New York . The formal presentation is scheduled ... addition, Mr. Krakauer and Jorgen B. Hansen , President ... the day. An audio webcast will be ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2
Cached News: